Filing Flows › C4 Therapeutics (CCCC) › Q3 2026 › vs Q3 2025
C4 Therapeutics (CCCC) Q3 2026 vs Q3 2025 (year over year)
C4 Therapeutics's revenue fell $2.8M (-25%) from $11.2M in Q3 2025 to $8.5M in Q3 2026.
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.5M | $11.2M | −$2.8M | -25% |
| Other income, net | $2.8M | $2.2M | $507K | +23% |
| Net loss | $21.8M | $32.2M | −$10.3M | -32% |
| Costs & expenses | $33.1M | $45.6M | −$12.6M | -28% |
| Operating costs | $33.1M | $45.6M | −$12.6M | -28% |
| Research & development | $24.8M | $26.0M | −$1.2M | -5% |
| General & admin | $8.3M | $8.9M | −$659K | -7% |
| Operating cash sources | $29.3M | $36.3M | −$7.0M | -19% |
| Depreciation | $320K | $460K | −$140K | -30% |
| Share-based compensation | $3.0M | $4.6M | −$1.6M | -35% |
| Cash used in operations | $26.0M | $31.2M | −$5.2M | -17% |
| Net loss absorbed | $21.8M | $32.2M | −$10.3M | -32% |
| Working capital & other | $7.4M | $4.1M | $3.3M | +81% |
Questions
How much did C4 Therapeutics's revenue grow year over year in Q3 2026?
C4 Therapeutics's revenue fell $2.8M (-25%) from $11.2M in Q3 2025 to $8.5M in Q3 2026.